Market Size of Global Immunomodulators Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 5.40 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Immunomodulators Market Analysis
The immunomodulators market is expected to register a CAGR of 5.4% over the forecast period 2022-2027.
The coronavirus disease (COVID-19) pandemic has affected the market for immunomodulators adversely. The article 'COVID-19 and immunosuppression: a review of current clinical experiences and implications for ophthalmology patients taking immunosuppressive drugs' published in 2022, by the British Journal of Ophthalmology, explains that immune suppressants have been widely used by doctors to treat chronic inflammatory illnesses, it does come with a few drawbacks, one of which is an increased risk of infection. Additionally, tt is crucial that doctors should properly give instructions to patients while taking medications considering the present COVID-19 outbreak. Hence, the market of immunomodulators has been impacted during the COVID outbreak.
Further, the increasing rate of diseases post covid caused the immunomodulator market to grow at a faster pace. The article 'Immunotherapies and immunomodulatory approaches in clinical trials - a mini review' published in the Human Vaccines & Immunotherapeutics journal in 2021, reveals that due to the respiratory issues developed after covid in many patients despite age group lead to the rise of immunotherapies when there was limited availability of vaccines. Immunotherapies employing convalescent plasma, immunoglobulins, antibodies (monoclonal or polyclonal), and the use of immunomodulatory agents to boost immunity are valuable alternatives due to the lack of any vaccine or medicines against COVID-19.
Increasing Incidence of Chronic Diseases Such as Asthma, Allergic Conditions, Cancer, and Multiple Sclerosis causes the immunomodulators market to grow, for instance, the research published in American Cancer Society points out that because of population expansion and ageing, it is anticipated that by 2040 there would be 16.3 million cancer deaths and 27.5 million new cancer cases worldwide. Due to the rising frequency of risk factors like smoking, poor food, and physical inactivity in economically developing nations, the burden will likely grow in the future.
Furthermore, market players are engaged in marketing tactics such as mergers and acquisitions, as well as product launches for instance in October 2019, Pandion Therapeutics, Inc. and Astellas Pharma Inc. signed a license and collaboration agreement to collaborate on the discovery, production, and marketing of locally acting immunomodulators for pancreatic autoimmune disorders. For the treatment of autoimmune conditions, the agreement will allow the parties to integrate Pandion's modular biologics and functional immunology knowledge with Astellas' advanced medicines development and worldwide marketing expertise.
The evaluated market is expected to grow throughout the analysis period for the reasons stated. However, unfavorable regulatory policies limit the growth of the immunomodulators industry.
